Cargando…
Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer
Background: We hypothesized that non-small cell lung cancer (NSCLC) patients with a tumor positive for single nucleotide polymorphisms (SNPs) of the Excision Repair Cross Complementation Group 1 (ERCC-1) gene could be more genetically instable and consequently more responsive to a programmed cell de...
Autores principales: | Aiello, Marco Maria, Solinas, Cinzia, Santoni, Matteo, Battelli, Nicola, Restuccia, Nunzio, Latteri, Fiorenza, Paratore, Sabrina, Verderame, Francesco, Albanese, Giuseppina Valeria, Bruzzi, Paolo, Soto Parra, Hector Josè |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493643/ https://www.ncbi.nlm.nih.gov/pubmed/32983959 http://dx.doi.org/10.3389/fonc.2020.01167 |
Ejemplares similares
-
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
por: Gebbia, Vittorio, et al.
Publicado: (2020) -
Nucleotide excision repair: a versatile and smart toolkit: Nucleotide excision repair
por: Zhang, Xiping, et al.
Publicado: (2022) -
Nucleotide Excision Repair in Caenorhabditis elegans
por: Lans, Hannes, et al.
Publicado: (2011) -
Epigenetic Regulation of Nucleotide Excision Repair
por: Li, Wentao, et al.
Publicado: (2022) -
Monitoring blood biomarkers to predict nivolumab effectiveness in
NSCLC patients
por: Passiglia, Francesco, et al.
Publicado: (2019)